Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Long-term Extended Access Protocol for Rapastinel as Adjunctive or Monotherapy Treatment in Patients With Major Depressive Disorder

NCT03668600 is registered in ClinicalTrials.gov with Naurex, Inc, an affiliate of Allergan plc as lead sponsor.

NCT NCT03668600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03668600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Long-term Extended Access Protocol for Rapastinel as Adjunctive or Monotherapy Treatment in Patients With Major Depressive Disorder
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Phase
Phase 3
Overall status
Terminated
Start date
August 23, 2018
Completion date
July 3, 2019
Enrollment
230 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major